Cardio-oncología y cardiotoxicidad

  1. Herrera Flores, C. 1
  2. Zatarain Nicolás, E. 1
  3. Bermejo, J. 1
  4. Fernández Avilés, F. 1
  1. 1 Servicio de Cardiología, Hospital General Universitario Gregorio Marañón, Madrid, España Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, España Centro de Investigación Biomédica en Red Cardiovascular (CIBER-CV), Instituto de Salud Carlos III, Madrid, España Universidad Complutense de Madrid, Madrid, España
Journal:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Year of publication: 2021

Issue Title: Enfermedades cardiovasculares (VII)

Series: 13

Issue: 41

Pages: 2390-2398

Type: Article

DOI: 10.1016/J.MED.2021.09.013 DIALNET GOOGLE SCHOLAR

More publications in: Medicine: Programa de Formación Médica Continuada Acreditado

Abstract

Cardio-oncology is a discipline that takes a comprehensive approach to cardiovascular disease in the cancer patient, in the presence of active cancer and in surviving patients. The modern concept of cardiotoxicity encompasses not only ventricular dysfunction and heart failure, but all toxic effects causing ischaemic heart disease, arrhythmias, systemic and pulmonary arterial hypertension, valvular heart disease, myocarditis, pericardial and thromboembolic disease. Cardiac imaging is the main tool for diagnosing and monitoring cardiovascular toxicity, and is complemented using biomarkers of myocardial injury. Management of toxic effects is based on the control of cardiovascular risk factors and heart-healthy lifestyles, introduction of heart failure drugs in the event of impaired ventricular function, and multidisciplinary assessment of the discontinuation of cancer treatment or use of alternative regimens, as well as cardioprotectors or less cardiotoxic formulations. After anti-tumour treatment has been completed, long-term cardiotoxicity surveillance should be continued in most patients, and and schedules for long-term follow-up of survivors are necessary.

Bibliographic References

  • Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F. Cardiovascular toxicity related to cancer treatment: A pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc. 2020;9:e018403.
  • Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020;13:431-50.
  • Buza V, Rajagopalan B, Curtis AB. Cancer treatment induced arrhythmias: Focus on chemotherapy and targeted therapies. Circ Arrhythm Electrophysiol. 2017;10(8):e005443.
  • Cardinale D, Iacopo F, Cipolla CM. Cardiotoxicity of anthracyclines. Front Cardiovasc Med. 2020;7:26.
  • Celutkiene J, Pudil R, López-Fernández T, Grapsa J, Nihoyannopoulos P, Bergler-Klein J. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovas-cular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22:1504-24.
  • Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular complications of cancer therapy: Best practices in diagnosis, prevention, and management: Part 1. J Am Coll Cardiol. 2017;70:2536-51.
  • Chang HM, Okwuosa TM, Scarabelli T, Moudgil R, Yeh ETH. Cardiovascular complications of cancer therapy: Best practices in diagnosis, prevention, and management: Part 2. J Am Coll Cardiol. 2017;70:2552-65.
  • Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31: 171-90.
  • Dobson R, Ghosh AK, Ky B, Marwick T, Stout M, Harkness A. British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab. Echo Res Pract. 2021;8(1):G1-G18.
  • Gregorietti V, Fernández TL, Costa D, Chahla EO, Daniele AJ. Use of Sacubitril/valsartan in patients with cardio toxicity and heart failure due to chemotherapy. Cardiooncology. 2020;6:24.
  • Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. Nat Rev Cardiol. 2020;17:474-502.
  • Kim PY, Irizarry-Caro JA, Ramesh T, Iliescu C, López-Mattei JC. How to diagnose and manage qt prolongation in cancer patients. JACC: CardioOncology. 2021;3:145-9.
  • Liu JE, Barac A, Thavendiranathan P, Scherrer-Crosbie M. Strain imaging in cardio-oncology. JACC: CardioOncology. 2020;2:677-89.
  • López-Fernández T, Martín García A, Santaballa Beltrán A, Montero Luis Á, García Sanz R, Mazón Ramos P. Cardio-oncohematología en la práctica clínica. Documento de consenso y recomendaciones. Rev Esp Cardiol. 2017;70:474-86.
  • López-Fernández T, Thavendiranathan P. Nuevas técnicas de imagen cardiaca en la detección precoz de cardiotoxicidad secundaria a tratamientos oncológicos. Rev Esp Cardiol. 2017;70:487-95.
  • López-Sendon J, Álvarez-Ortega C, Zamora Aunon P, Buño Soto A, Lyon AR, Farmakis D. Classification, prevalence, and outcomes of anticancer therapy induced cardiotoxicity: the CARDIOTOX registry. Eur Heart J. 2020;41:1720-9.
  • Lyon AR, Dent S, Stanway S, Earl H, Brezden-Masley C, Cohen-Solal A. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collabora-tion with the International Cardio-Oncology Society. Eur J Heart Fail. 2020;22:1945-60.
  • Martín García A, Mitroi C, Mazón Ramos P, García Sanz R, Virizuela JA, Arenas M. Estratificación, monitorización y control del riesgo cardiovascular en pacientes con cáncer. Documento de consenso de SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC y AECC. 2021;74(5):438-48.
  • Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063-93.
  • Plana JC, Thavendiranathan P, Bucciarelli-Ducci C, Lancellotti P. Multimodality imaging in the assessment of cardiovascular toxicity in the cancer patient. JACC Cardiovasc Imaging. 2018;11:1173-86.
  • Pudil R, Mueller C, Celutkiene J, Henriksen PA, Lenihan D, Dent S. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22:1966-83.
  • Saunderson CED, Plein S, Manisty CH. Role of cardiovascular magnetic resonance imaging in cardio-oncology. Eur Heart J Cardiovasc Imaging. 2021 Mar 22;22(4):383-96.
  • Vaduganathan M, Hirji SA, Qamar A, Bajaj N, Gupta A, Zaha V. Efficacy of neurohormonal therapies in preventing cardiotoxicity in patients with cancer undergoing chemotherapy. JACC CardioOncol. 2019;1:54-65.
  • Zhang L, Reynolds KL, Lyon AR, Palaskas N, Neilan TG. The evolving immunotherapy landscape and the epidemiology, diagnosis, and management of cardiotoxicity. JACC CardioOncol. 2021;3(1): 35-47.
Data source: Dialnet